Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Atlassian Corporation PLC — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Atlassian Corporation PLC trades at $204.1 (market cap $52.66B). The key difference: Atlassian Corporation PLC is far larger — about 7× Spyre Therapeutics Inc. Common Stock's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Atlassian Corporation PLC for 65 Days on average.
| SYRE | TEAM | |
|---|---|---|
Market Cap | $7.52B | $52.66B |
Volume | 1,441,031 | 2,601,329 |
Sector | Health | Technology |
52-Week High | $108.92 | $208.04 |
52-Week Low | $22.18 | $57.15 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $6.52B | $52.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Atlassian (TEAM) trades at $204.66, down 1.49% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong revenue growth, improving net losses, and consistent earnings beats, though profitability metrics remain negative. Recent news highlights AI-driven growth catalysts and cloud momentum.
The outlook is positive given analyst consensus and AI adoption, but high valuation ratios and persistent net losses pose risks. Upside is supported by a large addressable market and subscription growth, while competition and execution challenges are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
